Edge Therapeuticsincwas A Clinical Stage Biotechnology Company Focused On Developing Therapies For Acute Neurological Conditionsthe Company Specialized In Transforming Fda Approved Drugs To Address Unmet Needs In Neurological Careparticularly In Hospital Settingsin Late 2018Edge Shifted Its Strategic Focus Toward Oncology Through A Merger With Pds Biotechnology Corporationwhich Is Known For Its Work In Cancer Immunotherapies Following The Mergerthe Combined Entity Aimed To Advance Cancer Treatments Using Pdsae S Proprietary Versamuneaplatformwhich Enhances T Cell Activation Against Tumorsone Of The Lead Candidatespds0101Targets Hpv Induced Cancers And Is Set For Late Stage Clinical Trialsthe Merger Was Designed To Create A Strong Oncology Pipeline And Ensure Sufficient Funding For Ongoing Operationsbrian Aleuthner Served As President And Ceoguiding The Companyae S Vision To Leverage Innovative Technologies In Immuno Oncology
